Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Function first: a powerful approach to post-genomic drug discovery.

Stephen F Betz1, Susan M Baxter, Jacquelyn S Fetrow

  • 1GeneFormatics, 5830 Oberlin Drive, Suite 200, San Diego, CA 92121, USA.

Drug Discovery Today
|January 28, 2003
PubMed
Summary

Pharmaceutical researchers use proteomic-scale strategies to identify protein function, accelerating the discovery of drug leads. This approach enhances the identification of valid protein targets for drug development.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Discovery of CRN04894: A Novel Potent Selective MC2R Antagonist.

ACS medicinal chemistry letters·2024
Same author

A selective nonpeptide somatostatin receptor 5 agonist effectively decreases insulin secretion in hyperinsulinism.

The Journal of biological chemistry·2023
Same author

Discovery of Paltusotine (CRN00808), a Potent, Selective, and Orally Bioavailable Non-peptide SST2 Agonist.

ACS medicinal chemistry letters·2023
Same author

Somatostatin receptors in congenital hyperinsulinism: Biology to bedside.

Frontiers in endocrinology·2022
Same author

Discovery of 4-(3-aminopyrrolidinyl)-3-aryl-5-(benzimidazol-2-yl)-pyridines as potent and selective SST5 agonists for the treatment of congenital hyperinsulinism.

Bioorganic & medicinal chemistry letters·2022
Same author

Paltusotine, a novel oral once-daily nonpeptide SST2 receptor agonist, suppresses GH and IGF-1 in healthy volunteers.

Pituitary·2022

Area of Science:

  • Drug discovery and development
  • Proteomics
  • Bioinformatics

Background:

  • The post-genomic era necessitates efficient methods for evaluating protein sequences.
  • Identifying drug targets and leads requires understanding protein function and structure.
  • Current pharmaceutical research faces challenges in prioritizing targets from vast proteomic data.

Purpose of the Study:

  • To review proteomic-scale approaches for identifying protein function.
  • To highlight strategies for accelerating lead discovery in pharmaceutical research.
  • To emphasize the importance of functional genomics in target identification.

Main Methods:

  • Review of current literature on proteomic-scale functional identification.
  • Analysis of strategies for prioritizing protein families of interest.

Related Experiment Videos

  • Discussion of how functional insights aid small molecule lead discovery.

    • Main Results:

    • Functional genomics accelerates the identification of valid drug targets.
    • Proteomic-scale functional analysis improves efficiency in lead discovery pipelines.
    • Understanding protein function is key to developing selective small molecules.

    Conclusions:

    • Proteomic-scale functional identification is crucial for modern drug discovery.
    • Prioritizing protein function enhances resource allocation in pharmaceutical research.
    • This review provides a framework for leveraging proteomics in lead discovery.